Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37980651)

  • 1. STEAP3 is a prognostic biomarker that promotes glioma progression by regulating immune microenvironment and PI3K-AKT pathway.
    Song Z; Zhao Z; Zhu S; Jin Q; Shi Y; Zhang S; Wang Z; Wang Y; Zhao Z
    Cancer Biomark; 2023; 38(4):505-522. PubMed ID: 37980651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of six-transmembrane epithelial antigen of prostate 3 promotes the migration and invasion and predicts unfavorable prognosis in glioma.
    Deng L; Zeng S; Yi Q; Song L
    PeerJ; 2023; 11():e15136. PubMed ID: 37009153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IQGAP3 promotes the progression of glioma as an immune and prognostic marker.
    Gao X; Ge J; Gao X; Mei NA; Su Y; Shan S; Qian W; Guan J; Zhang Z; Wang L
    Oncol Res; 2024; 32(4):659-678. PubMed ID: 38560572
    [No Abstract]   [Full Text] [Related]  

  • 4. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
    Zhao WJ; Ou GY; Lin WW
    Front Immunol; 2021; 12():682415. PubMed ID: 34054873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arylsulfatase D is a prognostic biomarker that promotes glioma cells progression through JAK2/STAT3 pathway and M2 macrophage infiltration.
    Song Z; Zhao Z; Zhu S; Jin Q; Zhang S; Wang Z; Shen B; Wang Z; Zhao Z
    Front Oncol; 2023; 13():1228426. PubMed ID: 37766864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spinster homolog 2 reduces malignancies of glioblastoma via PTEN/PI3K/AKT pathway.
    Liang W; Liu M; Su Y; Wen Y; Wang L; Shan J; Zhao J; Xie K; Wang J
    IUBMB Life; 2024 Mar; 76(3):140-160. PubMed ID: 37728571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-transmembrane epithelial antigen of prostate 3 (STEAP3) is a potential prognostic biomarker in clear cell renal cell carcinoma that correlates with M2 macrophage infiltration and epithelial-mesenchymal.
    Wei H; Li Z; Zhao Y; Zhu S; Wen S; Quan C
    Cancer Rep (Hoboken); 2023 Aug; 6(8):e1824. PubMed ID: 37344930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
    Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
    Front Neurol; 2022; 13():977180. PubMed ID: 36353126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STEAP3 can predict the prognosis and shape the tumor microenvironment of clear cell renal cell carcinoma.
    Wu J; Bi Q; Zheng X; Cao H; Hao C; Sun Z; Wang W
    BMC Cancer; 2022 Nov; 22(1):1204. PubMed ID: 36424540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.
    Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S
    Front Immunol; 2023; 14():1128244. PubMed ID: 37818357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GDF15 expression in glioma is associated with malignant progression, immune microenvironment, and serves as a prognostic factor.
    Guo L; Chen Y; Hu S; Gao L; Tang N; Liu R; Qin Y; Ren C; Du S
    CNS Neurosci Ther; 2022 Jan; 28(1):158-171. PubMed ID: 34697897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SP140 inhibitor suppressing TRIM22 expression regulates glioma progress through PI3K/AKT signaling pathway.
    Li X; Li G; Li L; Gao B; Niu X; Wang Y; Wang Z
    Brain Behav; 2024 Mar; 14(3):e3465. PubMed ID: 38468469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and validation of RNA methylation-related alternative splicing gene signature for low-grade glioma to predict survival and immune landscapes.
    Ma C; Bao Y; Xu J; Xiao B; Li H
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):47-62. PubMed ID: 36528831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
    Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
    Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Qu S; Liu J; Wang H
    Front Immunol; 2021; 12():648416. PubMed ID: 33889156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of STEAP3-based molecular subtype and risk model in ovarian cancer.
    Zhao Z; Sun C; Hou J; Yu P; Wei Y; Bai R; Yang P
    J Ovarian Res; 2023 Jun; 16(1):126. PubMed ID: 37386521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
    Liu J; Xu K; Ma L; Wang Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combined signatures of telomere and immune cell landscape provide a prognostic and therapeutic biomarker in glioma.
    Han X; Yan Z; Fan K; Guan X; Hu B; Li X; Ou Y; Cui B; An L; Zhang Y; Gong J
    Front Immunol; 2023; 14():1220100. PubMed ID: 37662954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.